(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 September 2007 (20.09.2007)

PCT

(10) International Publication Number
WO 2007/104945 A3

(51) International Patent Classification:
C07K 14/495 (2006.01)

(21) International Application Number:
PCT/GB2007/000833

(22) International Filing Date: 12 March 2007 (12.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0604938.1 11 March 2006 (11.03.2006) GB

(71) Applicant *(for all designated States except US)*: **RENOVO LIMITED** [GB/GB]; The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FERGUSON, Mark, William, James** [GB/GB]; Renovo Limited, The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB). **MELLOR, Phillip** [GB/GB]; Renovo Limited, The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB). **LAVERTHY, Hugh, Gerard** [GB/GB]; Renovo Limited, The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB). **OCCLESTON, Nick** [GB/GB]; Renovo Limited, The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB). **O'KANE, Sharon** [GB/GB]; Renovo Limited, The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB). **ATKINSON, Emma** [GB/GB]; Renovo Limited, The Manchester Incubator Building, Grafton Street, Manchester M13 9XX (GB).

(74) Agent: **ARMSTRONG, Iain, Cheshire**; Marks & Clerk, Sussex House, 83-85 Mosley Street, Manchester M2 3LG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
15 May 2008

(54) Title: PROTEINS, NUCLEIC ACIDS AND MEDICAMENTS

(57) Abstract: The invention provides TGF-β3s, or fragments or derivatives thereof, wherein the alpha- helix-forming domain between amino acid residues (58) and (67) of full-length wild type TGF-β3 comprises at least one alpha-helix-stabilising substitution. The invention also provides TGF-β3s, or fragments or derivatives thereof, wherein the Glycine residue at position (63) of full-length wild type TGF-β3 is replaced with Proline. Further still, the invention provides TGF-β3s, or fragments or derivatives thereof, comprising a substitution of the Glutamic acid residue at position (12) of full-length wild type TGF-β3 and/or the Arginine residue at position (52) of full-length wild type TGF-β3. The invention also provides medicaments and methods of treatment using such TGF-β3s.

WO 2007/104945 A3